Cartesian Therapeutics Inc
RNAC
Market Cap$585.87M
Close$
$-4.66
144.8% downside
Current Fair Value
144.8% downsideOvervalued by 144.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $585.87 Million |
|---|---|
| Enterprise Value | $387.24 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-42.58 |
| Beta | 0 |
| Outstanding Shares | 5,414,074 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.52 |
|---|---|
| PEG | -0.31 |
| Price to Sales | 3.47 |
| Price to Book Ratio | -5.21 |
| Enterprise Value to Revenue | 19.05 |
| Enterprise Value to EBIT | -4.47 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -2.06 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Cartesian Therapeutics Inc
81 employees
CEO: Carsten Brunn selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vac...